Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study

Not yet recruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

January 1, 2031

Study Completion Date

December 31, 2031

Conditions
Prostate Cancer MetastaticProstate Cancer Metastatic to BoneProstate CancerProstate NeoplasmOligometastatic DiseaseOligometastasis
Interventions
PROCEDURE

Radical prostatectomy

Removal of the prostate and seminal vesicles.

RADIATION

Prostate irradiation

Radiation therapy of the prostate.

PROCEDURE

Surgical metastasectomy

Surgical removal of metastases.

RADIATION

Irradiation of metastases

Radiation therapy of metastases.

DRUG

Abiraterone acetate

Administered as part of multimodal treatment for oligometastatic prostate cancer

DRUG

Enzalutamide

Administered as part of multimodal treatment for oligometastatic prostate cancer

DRUG

Darolutamide

Administered as part of multimodal treatment for oligometastatic prostate cancer

DRUG

Apalutamide

Administered as part of multimodal treatment for oligometastatic prostate cancer

DRUG

Docetaxel

Administered as part of multimodal treatment for oligometastatic prostate cancer

DRUG

Lutetium-PSMA

Administered as part of multimodal treatment for oligometastatic prostate cancer

DRUG

Androgen deprivation treatment

Administered as part of multimodal treatment for oligometastatic prostate cancer

All Listed Sponsors
collaborator

IRCCS Ospedale San Raffaele

OTHER

collaborator

University Hospital of Cologne

OTHER

collaborator

St. Antonius Hospital

OTHER

collaborator

Istituto Europeo di Oncologia

OTHER

collaborator

University Hospital, Udine, Italy

OTHER

collaborator

Azienda Ospedaliera San Giovanni Battista

OTHER

collaborator

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice

OTHER

collaborator

Lund University

OTHER

collaborator

Medical University of Warsaw

OTHER

collaborator

Ziekenhuis Netwerk Antwerpen (ZNA)

OTHER

lead

Medical University of Vienna

OTHER

NCT06430411 - Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | Biotech Hunter | Biotech Hunter